Navigation Links
Oncology Physician Resource (OPR) Extends Agreement With OTN and Onmark as Oncology Services Partner
Date:11/5/2007

SOUTH SAN FRANCISCO, Calif., Nov. 5 /PRNewswire/ -- OTN, a leading physician services company and one of the largest distributors of products and services to the community physician market, and Onmark, a national group purchasing organization (GPO) for community-based practices, today announced that Oncology Physician Resource (OPR) has extended its existing partnership with OTN and Onmark for another year. Under the extended agreement, which is worth more than $200 million, OTN and Onmark will continue to provide OPR members with a wealth of oncology services, including drug distribution resources, technology and practice management solutions, clinical services, educational opportunities and GPO services.

OPR is a professional limited liability company owned by physician members who are dedicated to strengthening oncology practices through optimizing operational efficiencies and maximizing purchasing power. OPR represents approximately 100 oncologists in 42 practices at 77 sites located primarily in Michigan.

"We are continuing our successful partnership with OTN and Onmark because we are very pleased with their outstanding customer service, competitive pricing and commitment to innovation. We look forward to extending our relationship to continue to provide value to our OPR members," said Philip Stella, M.D., President and CEO of OPR.

OTN provides the broadest set of services, technology, pharmaceuticals, supportive care products and medical/surgical supplies to physicians practicing in the community-treatment setting. Under the extended agreement, OPR's members will continue to have access to OTN's Lynx(R) oncology-specific, web-based technology platform, which includes Lynx Mobile(TM), Lynx EMR(TM), Lynx Station,(TM) Lynx Practice Manager(TM); and other practice management tools, including Lynx Practice Intelligence(TM) Reports.

Through Onmark, OPR members will continue to have access to competitive contracts for oncology drugs from 17 leading pharmaceutical manufacturers, exclusive discounts and practice optimization services, including Onmark Regimen Profiler(TM), a web-based tool that helps practices and patients understand financial and clinical information for commonly used oncology treatment regimens. OPR practices can utilize Onmark's numerous education and support programs, as well as clinical webcasts and teleconferences, and clinical advisory boards.

"OPR's decision to continue its partnership with OTN is a testament to our solid track record of delivering products, technology and services to support the most cost-effective and highest-quality care, and to preserve the community-based treatment setting for oncology patients," said Gena Cook, Vice President, Sales and Marketing, OTN. "OTN continues to be focused on providing a broad set of customized solutions to physicians who practice in the community-based treatment setting. Customers like OPR recognize our dedication to the physician community and the value OTN brings to their practices."

About OTN

OTN, a McKesson Specialty company, is a leading physician services company that provides a broad set of customized solutions, including technology, pharmaceuticals, supportive care products and medical/surgical supplies, to physicians who practice in the community-based treatment setting. Through its innovative Lynx(R) technology platform, practice management tools and unsurpassed customer service, OTN helps physicians remain independent and improve practice efficiency while enabling them to focus on providing optimal patient care. OTN's specialty pharmacy, provides physicians and their patients with efficient delivery of medications to treat cancer, rheumatoid arthritis, infertility and other chronic conditions requiring the latest intravenous, injectable and oral medicines. OTN's affiliated group purchasing organization, Onmark, offers its members competitive contracts for oncology drugs and medical/surgical supplies, practice management tools and educational programs. OTN recently was named to the 2007 InformationWeek 500 and ranked #9 among companies in the healthcare industry and #102 among all 500 ranked companies. For more information, please visit http://www.myOTN.com

About Onmark

Onmark, a McKesson Specialty company, is a leading national group purchasing organization (GPO) for community-based practices. It is one of the largest GPOs in the community-based setting, with more than 2,400 members representing more than 4,000 physicians and over $6 billion in annual drug purchases. Through strategic relationships with OTN, pharmaceutical companies and industry experts, Onmark provides its members with access to a full portfolio of competitive contracts for pharmaceutical products and medical/surgical supplies, the most aggressive pricing available through OTN, practice management resources, clinical tools and educational programs. For information about the products, services and programs available to Onmark members, visit http://www.onmarkservices.com.


'/>"/>
SOURCE OTN
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 ... ... on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. ... eye-catching label design. Featuring one of the world’s most powerful antioxidants, molecular ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a ... Scooters . , Mobility Scooters give freedom to people who need help getting around. ... may be facing a long period of rehabilitation after an illness or accident. There ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a ... lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO of ... create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... GA (PRWEB) , ... December ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education ... Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on ... “We are honored to have Amy E. Herman present at this year’s conference, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Lexicon Pharmaceuticals, ... results today from a Phase 2 clinical study of ... Lexicon in collaboration with JDRF, the leading global organization ... of this Phase 2 clinical trial, which randomized a ... of a once-daily 400 mg dose of sotagliflozin compared ...
(Date:12/5/2016)... , December 5, 2016 According to ... Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), ... by MarketsandMarkets, the market is projected to reach USD 779.8 Million ... CAGR of 13.5% during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... PORTLAND, Oregon and PUNE, India ... a new report by Allied Market Research, titled, "Global Cancer ... the global revenue of cancer biomarkers market is projected to ... at a CAGR of 13.3% from 2016 to 2022. Omic ... share in 2015 and is expected to maintain its dominance ...
Breaking Medicine Technology: